关于皮肤血管肉瘤诊断和治疗的最新情况
Elizabeth Richards1, Joshua Schimmel1, Michael Renzi1
1Dr. Richards is from Cooper Medical School of Rowan University, Camden, New Jersey. Dr. Schimmel is from the Department of Dermatology, University of Colorado, Aurora. Dr. Renzi is from Dermatology Consultants, Lexington, Kentucky. Dr. Lawrence is from Cooper Dermatologic Surgery at Marlton, New Jersey.
Cutis
|July 23, 2024
概括
皮肤血管肉瘤 (CAS) 是一种罕见的癌症,常见于头部或部的老年男性. 通过皮肤检查和多学科护理的早期检测是获得更好的结果的关键.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
背景情况:
- 皮肤血管肉瘤 (CAS) 是一种罕见的,侵袭性的血管恶性瘤.
- 它主要影响60岁以上的白人男性,以头部,部或头皮上的形呈现.
研究的目的:
- 审查当前对皮肤血管肉瘤的理解和管理.
- 强调皮肤科医生在早期诊断中的作用和多学科护理的重要性.
主要方法:
- 对皮肤血管肉瘤现有文献的综述.
- 讨论诊断和治疗策略.
主要成果:
- 负边缘的手术是CAS的主要治疗方法.
- 莫斯微图外科手术 (MMS) 的作用仅限于特定情况下.
- 皮肤病学家的提高意识和彻底的皮肤检查对于及时诊断至关重要.
结论:
- 专门的癌症中心的多学科护理对于优化CAS等罕见和难以治疗的瘤的结果至关重要.
- 需要进一步的研究,以建立CAS管理的共识指南.
相关概念视频
01:30Skin Cancer
4.0K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.0K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K